Sign Up
Stories
Addex Therapeutics: Financial Updates and Collaboration
Share
ADOCIA Files 2023 Registration Document
Addex Therapeutics Enters ADS Offering A...
Addex Therapeutics Meeting
Overview
API
Addex Therapeutics, a Swiss pharmaceutical company, is set to release its Third Quarter 2023 Financial Results and participate in the Bio-Europe 2023 Conference. The company's CEO and key executives will provide business updates and review the company's product pipeline, including their lead drug candidate ADX71149 in a Phase 2 clinical trial for epilepsy treatment. Additionally, the company has extended its collaboration agreement with Indivior PLC for the discovery of novel oral GABAB positive allosteric modulator drug candidates for substance use disorder, with Indivior committing CHF 2.7 million to support research and discovery activities.
Ask a question
How might the participation in the Bio-Europe 2023 Conference contribute to Addex Therapeutics' visibility and potential partnerships in the pharmaceutical industry?
How might the release of the Third Quarter 2023 Financial Results impact Addex Therapeutics' stock performance and investor confidence?
What are the potential implications of the extended collaboration agreement with Indivior PLC for Addex Therapeutics' research and development efforts?
Article Frequency
0.2
0.4
0.6
0.8
1.0
May 2023
Jul 2023
Sep 2023
Nov 2023
Coverage